Weiterführende Literatur

  • Gerd Dannhardt
Part of the Optimierte Arzneimitteltherapie book series (ARZNEIMITTELTH.)

Weiterführende Literatur

  1. Chan TA, Morin PJ, Vogelstein B, Kinzler KW (1998) Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95:681–686PubMedCrossRefGoogle Scholar
  2. Classen M, Diehl V, Koch K-M Kochsiek K, Pongratz D, Scriba PC (1998) Differentialdiagnose, Innere Medizin. Urban & Schwarzenberg, München Wien BaltimoGoogle Scholar
  3. Classen M, Diehl V, Kochsiek K (1998) Innere Medizin. 4. Auflage, Urban & Schwarzenberg, München Wien BaltimoreGoogle Scholar
  4. Gilroy DW, Tomlinson A, Willoughby DA (1998) Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation. Inflamm Res 47:79–85PubMedCrossRefGoogle Scholar
  5. Hays SJ (1998) Therapeutic approaches to the treatment of neuroinflammatory diseases. Current Pharmaceutical Design 4:335–348PubMedGoogle Scholar
  6. Kelloff GJ, Boone CW (1994) Cancer chemopreventive agents: Drug development status and future prospects. J Cell Biochem Suppl. 20:197–205, 219-231, 240-252PubMedGoogle Scholar
  7. Kohl F (1997) 100 Jahre Acetylsalicylsäure: ein Sieg der pharmazeutischen Chemie. Pharm Ztg 142:2689–2698Google Scholar
  8. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC (1996) Structural basis for selective inhibition of cyclooxygenase-2 by antiinflammatory agents. Nature 384:644–648PubMedCrossRefGoogle Scholar
  9. Mathies H (1994) Chronischer Gelenkrheumatismus (Chronische Polyarthritis).Merkblätter Rheuma, Nr. 1.2, Deutsche Rheuma-LigaGoogle Scholar
  10. Mitchell JA, Evans TW (1998) Cyclooxygenase as a therapeutic target. Inflamm Res 47 (Supplement 2):88–92Google Scholar
  11. Morck H (1997) Aspirin — ein Jahrhundertpharmakon. Pharm Ztg, Supplement zu Nr. 38:1–15Google Scholar
  12. Mutschier E (1996) Arzneimittelwirkungen. 7.} Auflage, Wissenschaftliche Verlagsgesellschaft StuttgarGoogle Scholar
  13. Scarpignato C (1995) NSAID-induced gastroduodenal damage. Dig Dis 13 (Supplement 1):1–106Google Scholar
  14. Schiebler TH, Schmidt W, Zilles K (1997) Anatomie. 7. Aufl, Springer-Verlag, Berlin Heidelberg New York TokioGoogle Scholar
  15. Speight TM, Holford NHG (1996) Avery’s Drug Treatment. 4th Edition}, Adis InternationalGoogle Scholar
  16. Talley JJ (1997) Selective inhibitors of cyclooxygenase-2. Exp Opin Ther Patents 7:55–62Google Scholar
  17. Thews G, Mutschler E, Vaupel P (1999) Anatomie, Physiologie und Pathophysiologic des Menschen. 5. Auflage, Wissenschaftliche Verlagsgesellschaft StuttgartGoogle Scholar
  18. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705–716PubMedCrossRefGoogle Scholar
  19. Vane JR, Botting RM (1995) New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 44:1–10PubMedCrossRefGoogle Scholar
  20. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G (1994) Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 107:175–179Google Scholar
  21. Wessinghage D (1984) Taschenatlas der Rheumatologie. Thieme Verlag, Stuttgart New YorkGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • Gerd Dannhardt
    • 1
  1. 1.Institut für PharmazieJohannes Gutenberg-UniversitätMainzGermany

Personalised recommendations